BRCA1/2 Mutations Linked With Inherited Ovarian Cancer Risk

Share this content:
BRCA1/2 gene mutations may be associated with an inherited risk of ovarian cancer regardless of family history.
BRCA1/2 gene mutations may be associated with an inherited risk of ovarian cancer regardless of family history.

BRCA1/2 gene mutations may be associated with an inherited risk of ovarian cancer regardless of family history, according to a Japanese population study published in Cancer.1

Ikuko Sakamoto, MD, and fellow researchers at the Yamanashi Prefectural Central Hospital in Kofu, Japan, examined 95 women with ovarian cancer who were treated from 2013 to 2015.

BRCA1/2 gene mutation tests were performed with next-generation sequencing in order to determine a link between germline mutations and hereditary risk. Among those patients, 12 were found to have deleterious mutations, with 5 in the BRCA1 group and 7 in the BRCA2 group.

In 36 patients who had a family history of the disease, 6 were found to have mutations in BRCA1 and BRCA2. Six of the 59 cases without family history were also found to have BRCA1/2 germline mutations, and there was no statistical difference between the groups.

RELATED: Adjuvant Hormone Therapy Boosts Survival in Epithelial Ovarian Cancer

The researchers also found that patients with mutations were diagnosed at advanced stages and had poor prognostic histological subtypes.

“This finding indicates that BRCA1/2 genetic testing should be performed for all patients with ovarian cancers,” the authors concluded.

Reference

  1. Sakamoto I, Hirotsu Y, Nakagomi H, et al. BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer. [published online ahead of print October 6, 2015]. Cancer. doi: 10.1002/cncr.29707.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters